These were not patents on a drug. They were patents on the methods used to find one. Pharmaceutical intellectual property normally turns on composition of matter and method of treatment, and a company infringes those by making, using or selling a product. A patent asserted against discovery methodology is infringed in the laboratory, years before there is anything to sell, by a company that may never reach a market at all. Black Diamond has now agreed to pay for a licence rather than find out whether the claims would have held.

• The licence is the consequential half, not the settlement. A confidential settlement ends a dispute and tells the market very little. A settlement carrying a licence agreement converts six patents from a litigation position into a recurring revenue stream, and establishes that at least one drug developer ran the arithmetic and concluded that paying was cheaper than fighting. First licensees are the hardest to obtain and by far the most valuable, because every subsequent target negotiates against a precedent rather than against a theory. Whatever Black Diamond paid, it has repriced the asset.
• Competitive frame: the exposure here is not oncology, it is platforms. Lab-based systems to find and refine drug candidates describes a very large share of what this industry has funded over the past five years, from high-throughput screening and encoded libraries through to computational refinement and machine-learning candidate selection. Any company whose pitch describes a discovery engine should have counsel read these six patents before the next financing rather than after the next complaint. Note where in the lifecycle the risk lands: before a lead is nominated, which is exactly when a company has the least cash available to defend itself. That asymmetry is the mechanism, not a side effect of it.
• What to watch, given that nothing was decided. Dismissal with prejudice closes this case and resolves no question of validity or scope. There is no claim construction, no invalidity finding and no appellate record, so the next defendant meets the same six patents, one more settlement to be cited against it, and nothing to rely on. Settling inside four months for an undisclosed sum is the rational choice for a single small-cap oncology company. Repeated across an industry, it is how an untested patent family becomes a tax. The things to establish are the patent numbers themselves and whether the same plaintiff has filed against anyone else, because a second suit would tell you this was a campaign rather than a dispute.